Cargando…

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding m...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Hong, Li, Gai-gai, Nie, Hao, Feng, Yang-yang, Guo, Guang-yu, Guo, Wen-liang, Tang, Zhou-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023812/
https://www.ncbi.nlm.nih.gov/pubmed/32061264
http://dx.doi.org/10.1186/s12883-020-01633-3
_version_ 1783498333501784064
author Deng, Hong
Li, Gai-gai
Nie, Hao
Feng, Yang-yang
Guo, Guang-yu
Guo, Wen-liang
Tang, Zhou-ping
author_facet Deng, Hong
Li, Gai-gai
Nie, Hao
Feng, Yang-yang
Guo, Guang-yu
Guo, Wen-liang
Tang, Zhou-ping
author_sort Deng, Hong
collection PubMed
description BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibody (CGRP mAb) for the preventive treatment of episodic migraine, and provide high-quality clinical evidence for migraine therapy. METHODS: A systematic electronic database search was conducted to identify the potentially relevant studies. Two independent authors performed data extraction and quality appraisal. Mean difference (MD) and risk ratio (RR) were pooled for continuous and dichotomous data, respectively. The significance levels, weighted effect sizes and homogeneity of variance were calculated. RESULTS: Eleven high-quality randomized control trials that collectively included 4402 patients were included in this meta-analysis. Compared to placebo group, CGRP mAb therapy resulted in a reduction of monthly migraine days [weighted mean difference (WMD) = − 1.44, 95% CI = (− 1.68,− 1.19)] and acute migraine-specific medication days [WMD = − 1.28, 95% CI = (− 1.66,− 0.90)], with an improvement in 50% responder rate [RR = 1.51, 95% CI = (1.37,1.66)]. In addition, the adverse events (AEs) and treatment withdrawal rates due to AEs were not significantly different between CGRP mAb and placebo groups. Similar efficacy and safety results were obtained for erenumab, fremanezumab, and galcanezumab in subgroup analysis. CONCLUSIONS: The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine.
format Online
Article
Text
id pubmed-7023812
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70238122020-02-20 Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis Deng, Hong Li, Gai-gai Nie, Hao Feng, Yang-yang Guo, Guang-yu Guo, Wen-liang Tang, Zhou-ping BMC Neurol Review BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibody (CGRP mAb) for the preventive treatment of episodic migraine, and provide high-quality clinical evidence for migraine therapy. METHODS: A systematic electronic database search was conducted to identify the potentially relevant studies. Two independent authors performed data extraction and quality appraisal. Mean difference (MD) and risk ratio (RR) were pooled for continuous and dichotomous data, respectively. The significance levels, weighted effect sizes and homogeneity of variance were calculated. RESULTS: Eleven high-quality randomized control trials that collectively included 4402 patients were included in this meta-analysis. Compared to placebo group, CGRP mAb therapy resulted in a reduction of monthly migraine days [weighted mean difference (WMD) = − 1.44, 95% CI = (− 1.68,− 1.19)] and acute migraine-specific medication days [WMD = − 1.28, 95% CI = (− 1.66,− 0.90)], with an improvement in 50% responder rate [RR = 1.51, 95% CI = (1.37,1.66)]. In addition, the adverse events (AEs) and treatment withdrawal rates due to AEs were not significantly different between CGRP mAb and placebo groups. Similar efficacy and safety results were obtained for erenumab, fremanezumab, and galcanezumab in subgroup analysis. CONCLUSIONS: The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine. BioMed Central 2020-02-15 /pmc/articles/PMC7023812/ /pubmed/32061264 http://dx.doi.org/10.1186/s12883-020-01633-3 Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Deng, Hong
Li, Gai-gai
Nie, Hao
Feng, Yang-yang
Guo, Guang-yu
Guo, Wen-liang
Tang, Zhou-ping
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title_full Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title_fullStr Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title_short Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
title_sort efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023812/
https://www.ncbi.nlm.nih.gov/pubmed/32061264
http://dx.doi.org/10.1186/s12883-020-01633-3
work_keys_str_mv AT denghong efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT ligaigai efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT niehao efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT fengyangyang efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT guoguangyu efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT guowenliang efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis
AT tangzhouping efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis